1-2 of 2
Janusz Kloczko, Professor
Close
Sort by
Journal Articles

Phase 2 Study of Otlertuzumab (TRU-016), an Anti-CD37 ADAPTIR TM Protein, in Combination with Bendamustine Vs Bendamustine Alone in Patients with Relapsed Chronic Lymphocytic Leukemia (CLL) - Updated Results

Tadeusz Robak, MD, Andrzej Hellman, Javier Loscertales, MD, Ewa Lech-Maranda, MD PhD, John M. Pagel, MD PhD, Anthony R. Mato, MD, John C. Byrd, MD, Farrukh Awan, MD MS, Holger Hebart, MD, Jose A Garcia-Marco, MD PhD, Brian T. Hill, MD PhD, Michael Hallek, MD, Scott Stromatt, Janusz Kloczko, Professor
Journal: Blood
Blood (2014) 124 (21): 5642.
https://doi.org/10.1182/blood.V124.21.5642.5642
Published: 2014
Journal Articles

A Randomized, Multicenter Study (PALG CLL4/ ML 21283) Of Maintenance Treatment With Rituximab Versus Observation After Induction Treatment With Rituximab, Cladribine, and Cyclophosphamide (RCC) Regimen In Patients With Progressive Chronic Lymphocytic Leukemia: Interim Analysis

Tadeusz Robak, Jerzy Z. Blonski, MD, PhD, Krzysztof Jamroziak, MD, PhD, Aleksander Skotnicki, Professor, Magdalena Piotrowska, MD, Anatoly Uss, Professor, Janusz Kloczko, Professor, Jaroslaw Piszcz, Kazimierz Kuliczkowski, Professor, Tomasz Wrobel, MD PhD, Bozena Katarzyna Budziszewska, MD, PhD, Marta Fidecka, Piotr Smolewski, Professor
Journal: Blood
Blood (2013) 122 (21): 1640.
https://doi.org/10.1182/blood.V122.21.1640.1640
Published: 2013